Results 121 to 130 of about 169 (166)
Some of the next articles are maybe not open access.
The Evolution of the Serotonin-Dopamine Antagonist Concept
Journal of Clinical Psychopharmacology, 1995Before the dopamine hypothesis of schizophrenia became established, a serotonin (5-hydroxy-tryptamine) 5-HT hypothesis was popular. This was based on the hallucinogenic properties of lysergic acid diethlyamide and abnormal serotonin levels in schizophrenics. Suggestions that serotonin might be involved in the cause of schizophrenia or could be a target
openaire +2 more sources
Annual Review of Pharmacology and Toxicology, 1977
Publisher Summary The attention that brain dopamine has received in the 20 years since its identification in the mammalian brain is because of two factors: (a) the discovery that in Parkinson's disease, there is a specific deficit of nigro-striatal dopamine; this discovery formed the basis for the successful application of dopamine,s precursor L-dopa
openaire +3 more sources
Publisher Summary The attention that brain dopamine has received in the 20 years since its identification in the mammalian brain is because of two factors: (a) the discovery that in Parkinson's disease, there is a specific deficit of nigro-striatal dopamine; this discovery formed the basis for the successful application of dopamine,s precursor L-dopa
openaire +3 more sources
European Neuropsychopharmacology, 1991
Animal data suggest that a D1 antagonistic component in neuroleptic drugs counteracts development of dopamine supersensitivity and of tolerance to cataleptic effect. This has led to the hypothesis that neuroleptics with D1 antagonistic activity should cause a better suppression of tardive dyskinesia (TD) and less rebound aggravation after withdrawal ...
H, Lublin +7 more
openaire +2 more sources
Animal data suggest that a D1 antagonistic component in neuroleptic drugs counteracts development of dopamine supersensitivity and of tolerance to cataleptic effect. This has led to the hypothesis that neuroleptics with D1 antagonistic activity should cause a better suppression of tardive dyskinesia (TD) and less rebound aggravation after withdrawal ...
H, Lublin +7 more
openaire +2 more sources
The Journal of Pharmacology and Experimental Therapeutics, 2001
Antipsychotic drugs comprise a wide range of structurally diverse compounds and are considered to be antagonists at dopamine D2 receptors. High-resolution kinetic analyses of their antagonist properties was performed by monitoring dynamic dopamine (DA)-antagonist interactions at the recombinant human dopamine D(2short) receptor.
P J, Pauwels +4 more
openaire +2 more sources
Antipsychotic drugs comprise a wide range of structurally diverse compounds and are considered to be antagonists at dopamine D2 receptors. High-resolution kinetic analyses of their antagonist properties was performed by monitoring dynamic dopamine (DA)-antagonist interactions at the recombinant human dopamine D(2short) receptor.
P J, Pauwels +4 more
openaire +2 more sources
Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists
European Journal of Pharmacology, 1993The effect of dopamine D1 and D2 receptors agonists and antagonists on extracellular dopamine release was evaluated by microdialysis in the prefrontal cortex. Nomifensine (5 microM) was included in the Ringer solution during the experiments. Cortical dopamine release was tetrodotoxin- and calcium-dependent and was stimulated by high potassium (60 mM ...
M, Santiago, A, Machado, J, Cano
openaire +2 more sources
Tetrabenazine has properties of a dopamine receptor antagonist
Annals of Neurology, 1982AbstractTetrabenazine is considered to act in a manner similar to reserpine to reduce the involuntary movements of tardive dyskinesia or Huntington's disease and to improve psychoses. We determined that tetrabenazine also has properties of a dopamine receptor antagonist by testing the ability of tetrabenazine to block the inhibitory effect of dopamine ...
I S, Login, M J, Cronin, R M, MacLeod
openaire +2 more sources
Life Sciences, 1995
Dopaminergic compounds affect gastric secretion and response to experimental gastric mucosal injury. We showed previously that the novel dopamine D4 receptor antagonist, clozapine, significantly reduces gastric acid secretion and restraint stress-induced gastric lesions. Because the selectivity of clozapine for D4 receptors has recently been questioned,
openaire +2 more sources
Dopaminergic compounds affect gastric secretion and response to experimental gastric mucosal injury. We showed previously that the novel dopamine D4 receptor antagonist, clozapine, significantly reduces gastric acid secretion and restraint stress-induced gastric lesions. Because the selectivity of clozapine for D4 receptors has recently been questioned,
openaire +2 more sources
Metoclopramide: a dopamine receptor antagonist.
American family physician, 1990A dopamine receptor antagonist, metoclopramide has unique properties of increasing lower esophageal sphincter pressure and increasing the rate of gastric emptying. These gastrointestinal motility actions are useful in the treatment of diabetic gastroparesis and severe gastroesophageal reflux and in postoperative situations involving visceral atony ...
openaire +1 more source